ISLAMABAD: The Competition Commission of Pakistan (CCP) has granted approval for the transfer of trademarks for the pharmaceutical product Claforan from M/s Sanofi Aventis Deutschland GMBH to M/s Hoechst Pakistan Limited via a Trademark Assignment Agreement.

Hoechst Pakistan Limited, a publicly listed entity in Pakistan, focuses on the production, distribution, and trade of pharmaceutical goods. Sanofi Aventis Deutschland GMBH, a limited liability company based in Germany, is a leading manufacturer and distributor of pharmaceuticals throughout Europe. This deal enables Sanofi to hand over Claforan’s trademarks to Hoechst, establishing Hoechst as a significant contender in Pakistan’s pharmaceutical sector.CCP Holds Fourth Hearing on PTCL’s Acquisition of Telenor Pakistan

The CCP’s evaluation identified the relevant market as “Systemic Antibiotics” and categorized the deal as a horizontal merger. Hoechst Pakistan’s market share is expected to remain unchanged, as the company has already been manufacturing Claforan under a license from Sanofi Aventis. Consequently, this acquisition will not disrupt market equilibrium but will strategically bolster Hoechst’s standing.

The CCP determined that the acquisition would not result in market dominance and approved the transaction under Section 31(1)(d)(i) of the Competition Act. This decision ensures that the transaction maintains competitive stability within Pakistan’s systemic antibiotics market.